Blissway vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 76)
Blissway logo

Blissway

LeaderHealthcare

General

Computer vision fleet safety platform with real-time driver behavior monitoring and in-cab coaching; YC W20-backed competing with Samsara and Lytx for fleet accident reduction and insurance cost savings.

AI VisibilityBeta
Overall Score
B76
Category Rank
#74 of 596
AI Consensus
70%
Trend
stable
Per Platform
ChatGPT
70
Perplexity
71
Gemini
80

About

Blissway is a Tel Aviv-based road safety technology company using computer vision and AI to monitor and analyze driver behavior in real-time — providing fleets, trucking companies, and insurance carriers with dashcam-based driver risk scoring, real-time coaching alerts, and safety analytics that reduce accident rates and insurance costs. Backed by Y Combinator (W20) with $2.63-9.3 million raised across multiple rounds including a 2023 round supported by Maniv Mobility, Measured Ventures, and others, Blissway operates in the fleet safety and telematics market.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

76
Overall Score
81
#74
Category Rank
#17
70
AI Consensus
71
stable
Trend
stable
70
ChatGPT
80
71
Perplexity
75
80
Gemini
77
73
Claude
86
80
Grok
85

Key Details

Category
General
General
Tier
Leader
Leader
Entity Type
company
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.